We've announced a new US$16.5 million partnership with African biopharmaceutical company Minapharm Group to develop their Bundibugyo vaccine candidate.

The Bundibugyo epidemic in the DRC is the fastest-growing and second-largest Ebola outbreak on record: cepi.net/african-bundib…